Figure 3.

ULK1 is activated upon morusin treatment. A. ULK1 activation by morusin treatment. HeLa cells treated with either DMSO or morusin were subjected to immunoblotting with the indicated antibodies. B. Time course of ULK1 activation. HeLa cells were collected at the indicated time points following administration of morusin (30 uM), and subjected to immunoblotting with anti-ULK1 and anti-LC3-II antibodies. C. ULK1 depletion impairs morusin-induced LC3-II accumulation. HeLa cells either depleted or undepleted of ULK1 were treated with morusin, and subjected to immunoblotting with anti-LC3 and anti-ULK1 antibodies. D. ULK1 depletion impairs morusin-induced LC3 puncta accumulation. HeLa cells either depleted or undepleted of ULK1 were treated with morusin, and subjected to immunostaining with an anti-LC3 antibody. E. Wild-type MEF or Ulk1-KO MEF was treated with increasing amounts of morusin, and cells were collected after 6 hr of morusin treatment for immunoblotting. F. Wild-type MEF or Ulk1-KO MEF was treated with morusin (30 uM), and cells were collected at the indicated time points for immunoblotting. G. ULK1 knockout impairs morusin-induced accumulation of LC3 puncta. Wild-type MEF or Ulk1-KO MEF was treated with morusin, and subjected to immunostaining with an anti-LC3 antibody.